The loss of transbilayer asymmetry in cancer cells can be problematic, as it has been linked to reduced permeability to chemotherapeutic agents like cisplatin . However, it also offers a therapeutic advantage, as the exposure of aminophospholipids such as PE and PS on the outer leaflet creates targets for specific interventions. For instance, small peptides and nanovesicles like OPA and SapC-DOPS exploit this exposure to selectively kill cancer cells, representing a promising strategy for targeted therapy .